Extraurothelial recurrence after radical nephroureterectomy: preoperative predictors and survival

Int Urol Nephrol. 2015 May;47(5):775-9. doi: 10.1007/s11255-015-0946-8. Epub 2015 Mar 14.

Abstract

Objective: To identify the preoperative predictors of extraurothelial recurrence (EUR) after radical nephroureterectomy (RNU) in patients with upper tract urothelial carcinoma (UTUC).

Methods: A single-center series of 238 consecutive patients who were treated with RNU for UTUC was evaluated. Recurrence-free probabilities and cancer-specific survival (CSS) were estimated using the Kaplan-Meier method. Multivariate Cox proportional hazards regression models were used to evaluate the association between various clinicopathological factors and EUR.

Results: The median time to EUR was 17.6 months (range 3-73 months). EUR-free survival rates at 1, 3, 5, and 7 years were 87.8, 75.2, 73.5, and 72.6%, respectively. In multivariate Cox regression analyses, tumor stage (HR 27.4; 95% CI 7.83-95.8; p = 0.0001) and lymphovascular invasion (LVI) (HR 1.53; 95% CI 1.22-3.12; p = 0.01) were independently associated with EUR. In patients with EUR, 5-year CSS estimate was 29.2%. Tumor stage (HR 14.3; 95% CI 4.55-45.2; p < 0.001) and EUR (HR 2.7; 95% CI 1.54-4.73; p = 0.001) were the only independent predictors associated with worse CSS.

Conclusions: EUR significantly affected the prognosis in patients with UTUC managed by RNU. Patient with EUR had a greater probability of having higher tumor stages, higher tumor grades, and positive LVI. Tumor stage and LVI were independently associated with a worse EUR-free survival.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Blood Vessels / pathology
  • Carcinoma, Transitional Cell / drug therapy
  • Carcinoma, Transitional Cell / secondary*
  • Carcinoma, Transitional Cell / surgery
  • Chemotherapy, Adjuvant
  • Cisplatin / administration & dosage
  • Disease-Free Survival
  • Female
  • Humans
  • Kidney Neoplasms / drug therapy
  • Kidney Neoplasms / pathology*
  • Kidney Neoplasms / surgery
  • Lymphatic Metastasis
  • Lymphatic Vessels / pathology
  • Male
  • Middle Aged
  • Neoplasm Invasiveness
  • Neoplasm Recurrence, Local / pathology*
  • Neoplasm Staging
  • Nephrectomy*
  • Survival Rate
  • Ureter / surgery*
  • Ureteral Neoplasms / drug therapy
  • Ureteral Neoplasms / pathology*
  • Ureteral Neoplasms / surgery

Substances

  • Cisplatin